- Home
- Mutual Funds
- ICICI Prudential Mutual Fund
- ICICI Prudential Nifty Pharma Index Fund Direct-idcw
Fund Overview of ICICI Prudential Nifty Pharma Index Fund Direct-idcw
-
₹130.3 CrAUM
-
₹18.68NAV
-
0.50%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of ICICI Prudential Nifty Pharma Index Fund Direct-idcw
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 6.84% | NA | 6.12% |
| 6 Months | 6.85% | NA | 12.92% |
| 1 Year | 12.00% | 12.00% | 6.04% |
| 2 Years | 21.84% | 10.38% | 24.93% |
| 3 Years | 82.11% | 22.12% | 25.71% |
Compare ICICI Prudential Nifty Pharma Index Fund Direct-idcw with other mutual funds in the same category
ICICI Prudential Nifty Pharma Index Fund Direct-idcw
SBI Healthcare Opportunities Fund Direct Plan-growth
SBI Healthcare Opportunities Fund Direct Plan-idcw
Asset Allocation
equities
99.50%other assets or cash equivalents
0.50%ICICI Prudential Nifty Pharma Index Fund Direct-idcw is one Equity mutual fund offered by ICICI Prudential Mutual Fund. Launched on 14 Dec 2022, the fund aims Long term wealth creation solution. An index fund that seeks to track returns by investing in a basket of Nifty Pharma Index stocks and aims to achieve returns of the stated index, subject to tracking error. It manages assets worth ₹130.3 crore as on Sun May 31, 2026. The expense ratio stands at 0.5%. Fund Manager Manager Education Fund Manager Manager Education Fund Manager Manager EducationAbout ICICI Prudential Nifty Pharma Index Fund Direct-idcw
The portfolio allocation consists of 99.50% in equities, 0.50% in other assets or cash equivalents.Managed by Nishit Patel, it has delivered a return of 12.00% in the last year, a total return since inception of 19.48%.
Based on risk tolerance individuals may evaluate best sip investment during the overall investment planning.
Key Metrics of ICICI Prudential Nifty Pharma Index Fund Direct-idcw
-
Standard Deviation16.84%
-
Sharpe Ratio1.03%
-
Alpha-0.75%
-
Beta0.95%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth  |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from ICICI Prudential Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth
|
₹6,454 | -1.27% | 10.97% | 4.34% | 6.46% | 25.28% |
|
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth
|
₹6,454 | -1.21% | 11.20% | 4.74% | 7.32% | 26.34% |
|
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw
|
₹6,454 | -1.27% | 10.97% | 4.34% | 6.46% | 25.28% |
|
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw
|
₹6,454 | -1.21% | 11.20% | 4.74% | 7.32% | 26.34% |
|
ICICI Prudential Nifty Healthcare Etf-growth
|
₹203 | -2.14% | 6.73% | 5.97% | 9.56% | 21.76% |
|
ICICI Prudential Nifty Pharma Index Fund-growth
|
₹130 | -1.98% | 6.66% | 6.51% | 11.30% | 21.36% |
|
ICICI Prudential Nifty Pharma Index Fund Direct-growth
|
₹130 | -1.92% | 6.84% | 6.85% | 12.00% | 22.12% |
|
ICICI Prudential Nifty Pharma Index Fund-idcw
|
₹130 | -1.98% | 6.66% | 6.51% | 11.30% | 21.36% |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 21.33% | ₹27.79 Cr |
| Divi's Laboratories Ltd | Healthcare | 9.48% | ₹12.35 Cr |
| Dr. Reddy's Laboratories Ltd | Healthcare | 8.89% | ₹11.59 Cr |
| Cipla Ltd | Healthcare | 8.83% | ₹11.50 Cr |
| Lupin Ltd | Healthcare | 6.16% | ₹8.02 Cr |
| Laurus Labs Ltd | Healthcare | 5.93% | ₹7.73 Cr |
| Torrent Pharmaceuticals Ltd | Healthcare | 5.16% | ₹6.73 Cr |
| Aurobindo Pharma Ltd | Healthcare | 4.46% | ₹5.82 Cr |
| Glenmark Pharmaceuticals Ltd | Healthcare | 3.83% | ₹5.00 Cr |
| Alkem Laboratories Ltd | Healthcare | 3.60% | ₹4.69 Cr |
| Biocon Ltd | Healthcare | 3.43% | ₹4.46 Cr |
| Zydus Lifesciences Ltd | Healthcare | 3.02% | ₹3.93 Cr |
| Mankind Pharma Ltd. | Healthcare | 3.01% | ₹3.92 Cr |
| Ipca Laboratories Ltd | Healthcare | 2.37% | ₹3.09 Cr |
| Gland Pharma Ltd | Healthcare | 2.00% | ₹2.61 Cr |
| Jb Chemicals & Pharmaceuticals Ltd | Healthcare | 1.99% | ₹2.59 Cr |
| Wockhardt Ltd | Healthcare | 1.88% | ₹2.45 Cr |
| Abbott India Ltd | Healthcare | 1.55% | ₹2.02 Cr |
| Ajanta Pharma Ltd | Healthcare | 1.38% | ₹1.80 Cr |
| Piramal Pharma Ltd | Healthcare | 1.20% | ₹1.56 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
ICICI Prudential Nifty Pharma Index Fund Direct-idcw
What is the current AUM of ICICI Prudential Nifty Pharma Index Fund Direct-idcw?
As of Sun May 31, 2026, ICICI Prudential Nifty Pharma Index Fund Direct-idcw manages assets worth ₹130.3 crore
How has ICICI Prudential Nifty Pharma Index Fund Direct-idcw performed recently?
- 3 Months: 6.84%
- 6 Months: 6.85%
What is the long-term performance of ICICI Prudential Nifty Pharma Index Fund Direct-idcw?
- 3 Years CAGR: 22.12%
- Since Inception: 19.48%
What is the portfolio composition of ICICI Prudential Nifty Pharma Index Fund Direct-idcw?
Equity: 99.50%, Others: 0.50%.
Who manages ICICI Prudential Nifty Pharma Index Fund Direct-idcw?
ICICI Prudential Nifty Pharma Index Fund Direct-idcw is managed by Nishit Patel from ICICI Prudential Mutual Fund.
What is the market-cap allocation of ICICI Prudential Nifty Pharma Index Fund Direct-idcw?
Large Cap: 53.97%, Mid Cap: 37.55%, Small Cap: 8.49%.
Which are the top companies ICICI Prudential Nifty Pharma Index Fund Direct-idcw has invested in?
- Sun Pharmaceutical Industries Ltd – 21.33% of the fund's portfolio
- Divi's Laboratories Ltd – 9.48% of the fund's portfolio
- Dr. Reddy's Laboratories Ltd – 8.89% of the fund's portfolio
- Cipla Ltd – 8.83% of the fund's portfolio
- Lupin Ltd – 6.16% of the fund's portfolio
Which are the major sectors ICICI Prudential Nifty Pharma Index Fund Direct-idcw focuses on?
- Healthcare – 99.50% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
